DSM and Phynova unite for global distribution of Reducose

DSM-and-Phynova-unite-for-global-distribution-of-Reducose.jpg
Getty | AndreyPopov (Getty Images/iStockphoto)

DSM has signed a global distribution and collaboration agreement with Phynova, developer of natural healthcare products, for its blood glucose regulating ingredient Reducose.

The deal will allow Phynova to utilise DSM's expertise for its patented ingredient used to make products with high levels of sugar and other carbohydrates to become 'better for you' by reducing the absorption of these molecules by up to 40%.

Robert Miller, Phynova CEO, says DSM will provide their knowledge and capabilities in distribution, sales, product development, clinical research, regulatory approvals and marketing.

Ivo Lansbergen, VP global strategic marketing for DSM Human Nutrition and Health, says: “Phynova is a strategic partner for DSM to provide the right nutritional solutions to address the ever-growing health concerns linked to maintaining healthy blood glucose. The combined strengths of DSM and Phynova provide an excellent platform for addressing this major societal challenge.”

Reducose is a water extract of white mulberry leaves (Morus alba), a plant that has been used for centuries around the world as a food and animal feed.

The ingredient can be added in small quantities to food and drink or taken as a small supplement. It reduces the impact of high-glycaemic sugars, as well as other carbohydrates, on the body. 

Diabetes is a rapidly growing health issue with an estimated 425 million adults affected globally. The incidence of pre-diabetes is even higher with an estimated 390 million prediabetic adults in China alone.

Governments around the world are actively working to increase consumer awareness about healthy nutrition and reduction of high-glycaemic foods,

There is also a new generation of non-invasive wearable devices on the market that will be able to continuously monitor and make people aware of their blood glucose status.